Associated tags: Urinary tract infection, COVID, Therapy, Employment, Mergers and acquisitions, GLP, CSO, Bone marrow suppression, Lilly, Toxicology, Pharmacokinetics, Safety, OrbiMed, Omicron, Viral disease, Infection, Delta, SARS-CoV-2, Ritonavir, Aes, CDK, Oseltamivir
Locations: PA
Volunteering,
Mortality,
Cancer,
Hope,
Safety,
SARS-CoV-2,
Pharmacokinetics,
CDC,
COVID19,
Ageing,
Infection,
Pharmaceutical industry NEWTOWN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced that it completed dosing in the first cohort of the first-in-human Phase 1 study to evaluate travatrelvir (TRX01), an orally-available protease inhibitor, in development for treatment of COVID19. There have been no safety observations reported.
Key Points:
- “COVID-19 remains a significant global health concern, with SARS-CoV-2 infections posing a leading cause of mortality, especially among individuals aged 65 and above,” stated Werner Cautreels, Ph.D., Chief Executive Officer of Traws Pharma.
- “Our mission at Traws is to develop novel agents to treat respiratory viral diseases.
- We expect to report topline data from the Phase 1 study in H2 2024, followed by the initiation of an international Phase 2 safety and efficacy study."
- Robert R. Redfield, M.D., Chief Medical Officer of Traws Pharma and former director of the US Centers for Disease Control (CDC) added, “Travatrelvir has an exciting and unique profile.
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the “Merger”).
Key Points:
- NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the “Merger”).
- On April 1, 2024, Traws granted restricted stock equity awards to Werner Cautreels, Iain Dukes, Nikolay Savchuk, C. David Pauza and Robert Redfield, as an inducement for each of them to accept employment, which equity awards relate to, 200,000, 67,500, 67,500, 97,500 and 97,500 shares of Traws common stock.
- One-quarter (1/4) of the shares subject to each restricted stock equity award will vest on each of the first four anniversaries of the grant date, conditioned upon each employee’s continued employment on the vesting date(s).
- The inducement grants were approved by Traws’ Compensation Committee of the Board of Directors, as required by NASDAQ Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with NASDAQ Rule 5635(c)(4).
COVID19,
COVID,
Trawsfynydd,
Pfizer,
Drug,
Novartis,
General partnership,
Patient,
CYP,
Oseltamivir,
CDK,
Aes,
Ritonavir,
SARS-CoV-2,
Delta,
Infection,
Viral disease,
Omicron,
Therapy,
OrbiMed,
Safety,
Pharmacokinetics,
Toxicology,
Lilly,
Bone marrow suppression,
CSO,
GLP,
Mergers and acquisitions,
Pharmaceutical industry Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)
Key Points:
- Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)
Companies to host joint webcast, April 2, 2024 at 8:30 a.m.
- Under the terms of the agreement, Onconova acquired 100% of Trawsfynydd’s outstanding equity interests.
- These proceeds will be used to advance the Traws’ programs through multiple clinical data catalysts and complete the dose ranging study for narazaciclib.
- Topline data are expected H2 2024
Phase 2 study planned to be initiated in H2 2024.
